Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 1
2000 1
2001 1
2002 12
2003 16
2004 17
2005 14
2006 9
2007 12
2008 10
2009 11
2010 22
2011 22
2012 20
2013 19
2014 18
2015 15
2016 14
2017 20
2018 21
2019 14
2020 28
2021 38
2022 34
2023 34
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

378 results

Results by year

Filters applied: . Clear all
Page 1
SAPHO syndrome and pustulotic arthro-osteitis.
Kishimoto M, Taniguchi Y, Tsuji S, Ishihara Y, Deshpande GA, Maeda K, Okada M, Komagata Y, Kobayashi S, Okubo Y, Tomita T, Kaname S. Kishimoto M, et al. Among authors: okada m. Mod Rheumatol. 2022 Jul 1;32(4):665-674. doi: 10.1093/mr/roab103. Mod Rheumatol. 2022. PMID: 34967407 Review.
Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases.
Ota M, Nagafuchi Y, Hatano H, Ishigaki K, Terao C, Takeshima Y, Yanaoka H, Kobayashi S, Okubo M, Shirai H, Sugimori Y, Maeda J, Nakano M, Yamada S, Yoshida R, Tsuchiya H, Tsuchida Y, Akizuki S, Yoshifuji H, Ohmura K, Mimori T, Yoshida K, Kurosaka D, Okada M, Setoguchi K, Kaneko H, Ban N, Yabuki N, Matsuki K, Mutoh H, Oyama S, Okazaki M, Tsunoda H, Iwasaki Y, Sumitomo S, Shoda H, Kochi Y, Okada Y, Yamamoto K, Okamura T, Fujio K. Ota M, et al. Among authors: okada m. Cell. 2021 May 27;184(11):3006-3021.e17. doi: 10.1016/j.cell.2021.03.056. Epub 2021 May 1. Cell. 2021. PMID: 33930287 Free article.
The lysosomal Ragulator complex activates NLRP3 inflammasome in vivo via HDAC6.
Tsujimoto K, Jo T, Nagira D, Konaka H, Park JH, Yoshimura SI, Ninomiya A, Sugihara F, Hirayama T, Itotagawa E, Matsuzaki Y, Takaichi Y, Aoki W, Saita S, Nakamura S, Ballabio A, Nada S, Okada M, Takamatsu H, Kumanogoh A. Tsujimoto K, et al. Among authors: okada m. EMBO J. 2023 Jan 4;42(1):e111389. doi: 10.15252/embj.2022111389. Epub 2022 Nov 29. EMBO J. 2023. PMID: 36444797 Free PMC article.
Aortite chez une patiente recevant une chimiothérapie.
Fukui S, Kidoguchi G, Okada M. Fukui S, et al. Among authors: okada m. CMAJ. 2023 Feb 27;195(8):E315-E316. doi: 10.1503/cmaj.220584-f. CMAJ. 2023. PMID: 36849171 Free PMC article. French. No abstract available.
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, Hojnik M, Sapin C, Okada M, Caporali R, Gratacós J, Goupille P, Liu Leage S, Pillai S, Nash P. Smolen JS, et al. Among authors: okada m. Ann Rheum Dis. 2020 Oct;79(10):1310-1319. doi: 10.1136/annrheumdis-2020-217372. Epub 2020 Jul 13. Ann Rheum Dis. 2020. PMID: 32660977 Free PMC article. Clinical Trial.
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D. Stohl W, et al. Among authors: okada m. Arthritis Rheumatol. 2017 May;69(5):1016-1027. doi: 10.1002/art.40049. Epub 2017 Apr 7. Arthritis Rheumatol. 2017. PMID: 28118533 Free PMC article. Clinical Trial.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Among authors: okada m. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
Necrotizing Otitis Externa.
Suyama Y, Okada M, Nozaki T, Furukawa K. Suyama Y, et al. Among authors: okada m. Intern Med. 2019 Mar 15;58(6):895-896. doi: 10.2169/internalmedicine.1684-18. Epub 2018 Nov 19. Intern Med. 2019. PMID: 30449798 Free PMC article. No abstract available.
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, Lin CY, Braun DK, Lee CH, Gladman DD; SPIRIT-P1 Study Group. Mease PJ, et al. Among authors: okada m. Ann Rheum Dis. 2017 Jan;76(1):79-87. doi: 10.1136/annrheumdis-2016-209709. Epub 2016 Aug 23. Ann Rheum Dis. 2017. PMID: 27553214 Free PMC article. Clinical Trial.
Sarcoid Myofasciitis.
Rokutanda R, Tomishima Y, Okada M. Rokutanda R, et al. Among authors: okada m. Arthritis Rheumatol. 2017 Sep;69(9):1795. doi: 10.1002/art.40140. Epub 2017 Aug 1. Arthritis Rheumatol. 2017. PMID: 28464470 No abstract available.
378 results